Showing results (31-40 of 65) with videos related to

Sort By:
Pageof 7
Lung Cancer (Amsterdam, Netherlands)|February 29, 2008
Utility of 18FDG-PET for differentiating the grade of malignancy in thymic epithelial tumorsMasahiro Endo, Kazuo Nakagawa, Yasuhisa Ohde, et al.
Cancer Science|January 29, 2011
Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reportsTakehito Shukuya, Toshiaki Takahashi, Rieko Kaira, et al.
Annals of Nuclear Medicine|December 22, 2010
18F-FDG uptake on PET helps predict outcome and response after treatment in unresectable thymic epithelial tumorsKyoichi Kaira, Haruyasu Murakami, Satoru Miura, et al.
Oncology Reports|July 14, 2011
Expression of 4F2hc (CD98) in pulmonary neuroendocrine tumorsKyoichi Kaira, Yasuhisa Ohde, Masahiro Endo, et al.
Medical Oncology (Northwood, London, England)|September 26, 2009
Actual status of adjuvant chemotherapy for non-small-cell lung cancer at one Japanese cancer center: the need for increased cooperation between medical oncologists and surgeonsTakehito Shukuya, Toshiaki Takahashi, Akihiro Tamiya, et al.
International Journal of Clinical Oncology|March 4, 2010
Evaluation of S-1 as third- or further-line chemotherapy in advanced non-small-cell lung cancerAkira Ono, Tateaki Naito, Haruyasu Murakami, et al.
Anticancer Research|May 18, 2012
Prognostic factors and clinical outcome of patients with lung adenocarcinoma with carcinomatous meningitisYukiko Nakamura, Toshiaki Takahashi, Asuka Tsuya, et al.
Lung Cancer (Amsterdam, Netherlands)|June 23, 2009
Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancerKyoichi Kaira, Tateaki Naito, Toshiaki Takahashi, et al.
Investigational New Drugs|April 8, 2015
The efficacy of amrubicin on central nervous system metastases originating from small-cell lung cancer: a case series of eight patientsSatoru Miura, Kyoichi Kaira, Rieko Kaira, et al.
Investigational New Drugs|January 18, 2012
Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumorsToshiaki Takahashi, Narikazu Boku, Haruyasu Murakami, et al.
Pageof 7